PMID: 6975728Jan 1, 1981Paper

Ontogeny of transplantation immunity in the common frog, Rana temporaria L

Differentiation; Research in Biological Diversity
B Płytycz

Abstract

Viability of allografts exchanged between the field-collected individuals of the common frog, R. temporaria, was long in tadpoles grafted during and immediately after closing of operculum; median survival time (MST) was 26 and 18 days, respectively. This probably reflected the immaturity of the host immune system and temporary tolerance to weak transplantation antigens. Allograft viability was the shortest in tadpoles grafted at foot-paddle stage (MST, 11 days). It was independent from the origin and size of the grafts. Such rate of rejection might reflect a maximal immunological potential of the host and the absence of any suppressor factors in response to highly polymorphic frog transplantation antigens. A gradual prolongation of allograft viability was observed in animals grafted at final stages of metamorphosis, in froglets, and in sexually mature adults (MST: 13, 17, and 28 days, respectively). In particular age groups viability of allografts from sibling donors was longer and from nonsibling ones shorter than MST values cited above. Immunological memory of transplantation antigens did not disappear during the host metamorphosis, as MST (10 days) of second-set allografts in metamorphosing hosts sensitized during larval lif...Continue Reading

References

Aug 1, 1974·Proceedings of the National Academy of Sciences of the United States of America·A C WilsonL R Maxson
Jan 1, 1981·Developmental and Comparative Immunology·B Płlytycz
Jan 1, 1980·Developmental and Comparative Immunology·B Płytycz
Feb 1, 1980·Differentiation; Research in Biological Diversity·L Du Pasquier, C C Bernard

❮ Previous
Next ❯

Citations

Jan 1, 1984·Immunogenetics·B Płytycz
Jan 1, 1984·Developmental and Comparative Immunology·B Płytycz
Aug 6, 2011·Integrative and Comparative Biology·Louise A Rollins-SmithDouglas C Woodhams
Jan 23, 1999·Immunological Reviews·L A Rollins-Smith
Jan 22, 1986·Proceedings of the Royal Society of London. Series B, Containing Papers of a Biological Character·L C Smith, W H Hildemann

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.